| |
Hormone receptor-positive tumors (n=25)
|
Hormone receptor-negative tumors (n=17)
|
|---|
| |
No. of Patients (No. of events)
|
3-year estimates
|
95% CI
|
P-value
|
No. of Patients (No. of events)
|
3-year estimates
|
95% CI
|
P-value
|
|---|
|
All patients
|
25 (7)
|
0.76
|
0.58-0.95
| |
17 (5)
|
0.69
|
0.42-0.95
| |
|
Response to neoadjuvant CT
| | | | | | | | |
|
pCR (grade 3)
|
8 (1)
|
0.81
|
0.58-1.05
|
0.485
|
12 (3)
|
1.0
|
-
|
0.906
|
|
No pCR (grade 0~2)
|
14(4)
|
0.77
|
0.49-1.05
| |
3 (1)
|
0.69
|
0.39-0.99
| |
|
HER2 copy numbers
| | | | | | | | |
|
≤ 2.0
|
6 (4)
|
0.60
|
0.17-1.03
|
0.12
|
2 (1)
|
0.50
|
−0.19-1.19
|
NA
|
|
> 2.0
|
19 (3)
|
0.81
|
0.62-1.01
| |
15 (4)
|
0.74
|
0.47-1.00
| |
|
Wild-type HER2 mRNA
| | | | | | | | |
|
< 400
|
14 (5)
|
0.67
|
0.43-0.91
|
0.054
|
6 (3)
|
0.33
|
−0.17-0.83
|
0.196
|
|
≥ 400
|
6 (0)
|
1.0
|
-
| |
11 (2)
|
0.86
|
0.60-1.12
| |
|
∆16HER2 mRNA
| | | | | | | | |
|
< 4.5
|
14 (4)
|
0.74
|
0.53-0.96
|
0.283
|
3 (1)
|
0
|
0
|
0.832
|
|
≥ 4.5
|
6 (1)
|
0.80
|
0.45-1.15
| |
14 (4)
|
0.72
|
0.45-1.00
| |
|
Percentages of ∆16HER2 mRNA
| | | | | | | | |
|
< 2.4%
|
17 (3)
|
0.78
|
0.59-0.97
|
0.143
|
14 (3)
|
0.77
|
0.49-1.00
|
0.073
|
|
≥ 2.4%
|
3 (2)
|
0.67
|
0.13-1.20
| |
3 (2)
|
0.33
|
−0.20-0.87
| |
|
PIK3CA (exons 9 and 20)
| | | | | | | | |
|
Wild-type
|
21 (4)
|
0.89
|
0.75-1.03
|
0.006
|
15 (5)
|
0.65
|
0.37-0.94
|
NA
|
|
Mutated
|
4 (3)
|
0.25
|
−0.17-0.67
| |
2 (0)
|
1.0
|
-
| |
|
PIK3CA (exons 9 and 20)
| | | | | | | | |
|
Wild-type + Norma l+ Loss +UPD
|
16 (1)
|
1.0
|
-
|
0.001
|
12 (5)
|
0.57
|
0.25-0.89
|
0.2
|
|
Mutated + Gain
|
9 (6)
|
0.40
|
0.06-0.74
| |
5 (0)
|
1.0
|
-
| |
|
PTEN
| | | | | | | | |
|
Normal + Gain + UPD
|
20 (6)
|
0.76
|
0.55-0.97
|
0.814
|
17 (5)
|
0.69
|
0.42-0.95
|
NA
|
|
Loss
|
5 (1)
|
0.80
|
0.45-1.15
| |
0
|
-
|
-
| |
|
INPP4B
| | | | | | | | |
|
Normal + Gain + UPD
|
21 (4)
|
0.83
|
0.65-1.01
|
0.133
|
15 (4)
|
0.75
|
0.49-1.00
|
NA
|
|
Loss
|
4 (3)
|
0.50
|
0.01-0.99
| |
2 (1)
|
0.50
|
−0.19-1.19
| |
|
PI3KCA, PTEN, INPP4B
| | | | | | | | |
|
No aberrations*
|
12 (0)
|
1.0
|
-
|
0.002
|
10 (4)
|
0.59
|
0.23-0.95
|
0.312
|
|
Aberrations**
|
13 (7)
|
0.60
|
0.32-0.87
| |
7 (1)
|
0.75
|
0.33-1.17
| |
|
DEK
| | | | | | | | |
|
Normal
|
17 (3)
|
0.86
|
0.68-1.04
|
0.067
|
11 (2)
|
0.91
|
0.74-1.08
|
0.106
|
|
Gain
|
8 (4)
|
0.51
|
0.11-0.91
| |
6 (3)
|
0.30
|
−0.17-0.77
| |
|
FGFR1
| | | | | | | | |
|
Normal + Loss + UPD
|
17 (5)
|
0.72
|
0.49-0.96
|
0.94
|
12 (4)
|
0.59
|
0.28-0.91
|
0.69
|
|
Gain
|
8 (2)
|
0.86
|
0.60-1.12
| |
5 (1)
|
1.0
|
-
| |
|
CCND1
| | | | | | | | |
|
Normal + Loss
|
16 (2)
|
0.91
|
0.74-1.08
|
0.075
|
9 (2)
|
0.71
|
0.36-1.06
|
0.433
|
|
Gain
|
9 (5)
|
0.51
|
0.16-0.85
| |
8 (3)
|
0.67
|
0.29-1.04
| |
|
FOXA1
| | | | | | | | |
|
Normal + UPD
|
17 (1)
|
0.92
|
0.76-1.07
|
0.002
|
13 (5)
|
0.66
|
0.39-0.93
|
0.504
|
|
Gain
|
8 (6)
|
0.45
|
0.08-0.82
| |
4 (0)
|
1.0
|
-
| |
|
CDH3
| | | | | | | | |
|
Normal + Loss + UPD
|
20 (3)
|
0.88
|
0.73-1.04
|
0.007
|
17 (5)
|
0.69
|
0.42-0.95
|
NA
|
|
Gain
|
5 (4)
|
0.40
|
−0.03-0.83
| |
0
|
-
|
-
| |
|
BIRC5
| | | | | | | | |
|
Normal + Loss + UPD
|
19 (3)
|
0.86
|
0.68-1.04
|
0.016
|
8 (2)
|
0.75
|
0.45-1.05
|
0.235
|
|
Gain
|
6 (4)
|
0.44
|
0.01-0.88
| |
9 (3)
|
0.59
|
0.10-1.09
| |
|
MYBL2
| | | | | | | | |
|
Normal + Loss
|
16 (2)
|
0.92
|
0.78-1.07
|
0.015
|
14 (5)
|
0.66
|
0.39-0.94
|
0.539
|
|
Gain
|
9 (5)
|
0.48
|
0.11-0.84
| |
3 (0)
|
1.0
|
-
| |
|
AIB1
| | | | | | | | |
|
Normal + Loss
|
17 (2)
|
0.93
|
0.79-1.06
|
0.006
|
14 (5)
|
0.66
|
0.39-0.94
|
0.539
|
|
Gain
|
8 (5)
|
0.39
|
−0.01-0.78
| |
3 (0)
|
1.0
|
-
| |
- CI, confidence interval; CT, chemotherapy; NA, not applicable; *No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain, or UPD of PTEN or INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and loss of PTEN or INPP4B.
